A first-in-human phase 1 study of IO-202 (anti-LILRB4 mAb) in acute myeloid leukemia (AML) with monocytic differentiation and chronic myelomonocytic leukemia (CMML) patients

DiNardo, C., et al. European Hematology Association 2023. June 8–15, 2023

Previous
Previous

Poster presented—Targeting LILRB4 (ILT3) using IO-202 in patients with chronic myelomonocytic leukemia (CMML): interim efficacy, safety, and mechanism of action data from the Phase 1b expansion cohort

Next
Next

A Novel Bispecific LILRB4 x CD3 Antibody with Potent killing of Monocytic Acute Myeloid Leukemia Cells